0Y2 Stock Chart & Stats
€1.39
€0.00(0.00%)
At close: 4:00 PM EDT
€1.39
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€1.21 - €2.64
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€40.33M
Enterprise Value€10.19
Total Cash (Recent Filing)€21.36M
Total Debt (Recent Filing)€1.51M
Price to Earnings (P/E)―
Beta1.04
Next Earnings
Aug 06, 2026EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.69
Shares Outstanding26,585,258
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)1.76
Price to Sales (P/S)829.46
P/FCF Ratio-1.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€6.95Price Target Upside399.99% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.66
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory Progress For CORDStrom/EbstrocelAlignment with MHRA, a rapid PIP assessment and active MAA preparation materially de-risk the regulatory pathway for Ebstrocel in RDEB. Parallel EMA/FDA planning and documented endpoint guidance improve odds of conditional approval and future market access in an ultra-rare indication.
Secured Cord-tissue Supply And Manufacturing ValidationInitiating process-validation runs plus a long-term Anthony Nolan agreement strengthens manufacturing reproducibility and raw-material traceability. Reliable GMP supply and validated processes reduce scale-up and CMC risks that commonly block cell-therapy commercialization across global markets.
XPro Fast Track And Supportive Phase‑2 ImagingFast Track designation and independent MRI results supporting target engagement boost XPro’s development efficiency and regulatory dialogue. Coupled with biomarker-enriched signals, this structurally strengthens the program's differentiation and the design of a more efficient registrational adaptive trial.
Bears Say
Zero Revenue And Persistent Large LossesThe company remains pre-commercial with no product sales and substantial recurring losses, meaning it cannot self-fund operations long-term. Persistent negative profitability erodes equity, restricts reinvestment capacity, and increases reliance on external financing for development and commercialization.
Limited Cash Runway; Financing Need RiskA roughly one-year runway creates structural financing pressure that can force dilutive equity raises or deal-driven milestones. Fundraising demands can divert management focus, impose restrictive terms, and delay programs if capital markets or partner interest weaken over the medium term.
Material Reduction In R&D SpendCutting R&D materially lowers burn short-term but risks slowing trial enrollment, data generation and iterative optimization. Sustained lower investment could stretch timelines, reduce robustness of registrational packages, and weaken negotiating leverage with potential partners.
Inmune Bio News
0Y2 FAQ
What was Inmune Bio Inc’s price range in the past 12 months?
Inmune Bio Inc lowest stock price was €1.21 and its highest was €2.64 in the past 12 months.
What is Inmune Bio Inc’s market cap?
Inmune Bio Inc’s market cap is €40.33M.
When is Inmune Bio Inc’s upcoming earnings report date?
Inmune Bio Inc’s upcoming earnings report date is Aug 06, 2026 which is in 4 days.
How were Inmune Bio Inc’s earnings last quarter?
Inmune Bio Inc released its earnings results on May 07, 2026. The company reported -€0.173 earnings per share for the quarter, beating the consensus estimate of -€0.212 by €0.039.
Is Inmune Bio Inc overvalued?
According to Wall Street analysts Inmune Bio Inc’s price is currently Undervalued.
Does Inmune Bio Inc pay dividends?
Inmune Bio Inc does not currently pay dividends.
What is Inmune Bio Inc’s EPS estimate?
Inmune Bio Inc’s EPS estimate is -0.18.
How many shares outstanding does Inmune Bio Inc have?
Inmune Bio Inc has 26,585,258 shares outstanding.
What happened to Inmune Bio Inc’s price movement after its last earnings report?
Inmune Bio Inc reported an EPS of -€0.173 in its last earnings report, beating expectations of -€0.212. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Inmune Bio Inc?
Currently, no hedge funds are holding shares in DE:0Y2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Inmune Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€6.95 (399.99% Upside)
€6.95 (399.99% Upside)
Blogger Sentiment
Bullish
DE:0Y2 Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-36.16%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-31.70%
Trailing 12-Months
Company Description
Inmune Bio Inc
INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies. Its primary objective is to harness the body's innate immune system to combat various illnesses. The company is actively engaged in developing and bringing to market therapeutic candidates designed to address a spectrum of conditions such as blood cancers, solid tumors, and chronic inflammatory diseases. Its pipeline features key development programs including: INKmune: Aimed at treating women suffering from relapsed or refractory ovarian carcinoma and individuals diagnosed with high-risk myelodysplastic syndrome. INB03: An immunotherapy targeting patients with both hematologic malignancies and solid tumors. XPro1595: Under development for the treatment of Alzheimer's disease. INmune Bio holds licensing agreements with entities including Xencor, Inc., Immune Ventures, LLC, the University of Pittsburgh, and University College London. Established in 2015, INmune Bio is headquartered in Boca Raton, Florida.
0Y2 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed meaningful, tangible progress toward a key inflection point: CORDStrom advanced through regulatory planning (PIP approval), manufacturing validation runs began, and a long-term supply agreement was secured — all supportive milestones. XPro imaging work and partnership exploration were also positive. Offsetting these positives are schedule/regulatory timing shifts, a materially limited cash runway (funding through Q1 2027), and a large year-over-year reduction in R&D spend that could indicate slower near-term investment. Overall the call shows constructive execution on regulatory and manufacturing fronts but meaningful financing and execution risks remain.View all DE:0Y2 earnings summaries0Y2 Stock 12 Month Forecast
Average Price Target
€6.95
▲(399.99% Upside)
Technical Analysis
Veru
―
Karyopharm Therapeutics
―
Cue Biopharma
―
Celularity
―
Jupiter Neurosciences, Inc.
―